文献速递肝病

使用凝血调节蛋白-PAR1抑制剂沃拉帕沙靶向衰老肝细胞可改善NAFLD进展

Targeting senescent hepatocytes using the thrombomodulin-PAR1 inhibitor vorapaxar ameliorates NAFLD progression.
PubMed 文献 · Hepatology · 2023-04-11

该研究在NAFLD患者肝活检中评估THBD-PAR1通路,并在小鼠中通过过表达p16诱导肝细胞衰老,发现衰老肝细胞上调THBD-PAR1信号并表达促纤维化因子;在遗传性肥胖或西方饮食/CCl4所致NASH小鼠模型中,沃拉帕沙阻断PAR1信号可减少衰老但存活的肝细胞、安全改善NASH和纤维化。

要点

  • 衰老肝细胞上调凝血调节蛋白-PAR1信号以维持存活并表达促纤维化因子。
  • 沃拉帕沙阻断PAR1信号可减少「不死」衰老肝细胞负荷,安全改善NASH和纤维化。
  • THBD-PAR1信号轴是NASH的潜在治疗靶点。

核心结论

  • THBD-PAR1信号轴是NASH的新治疗靶点,阻断该通路可防止产生促适应不良肝修复因子的衰老但存活肝细胞积累。

研究设计与样本

  • 研究评估NAFLD患者肝活检中的THBD-PAR1通路,并使用 Chow-fed 小鼠经病毒载体过表达肝细胞p16诱导复制性衰老。
  • 使用遗传性肥胖或西方饮食/CCl4所致NASH小鼠模型,以沃拉帕沙治疗以确定对肝细胞衰老和肝损伤的影响。

主要发现

  • 诱导衰老上调肝细胞THBD-PAR1信号轴并诱导促纤维化因子(包括hedgehog配体)表达。
  • NAFLD中肝细胞THBD-PAR1信号增加,支持持续性肝细胞衰老,限制有效肝再生并促进适应不良修复。
  • 沃拉帕沙抑制PAR1信号可中断该过程,减少「不死」衰老细胞负荷,并在持续脂毒性应激下安全改善NASH和纤维化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Senescent hepatocytes accumulate in parallel with fibrosis progression during NASH. The mechanisms that enable progressive expansion of nonreplicating cell populations and the significance of that process in determining NASH outcomes are unclear. Senescing cells upregulate thrombomodulin-protease-activated receptor-1 (THBD-PAR1) signaling to remain viable. Vorapaxar blocks the activity of that pathway. We used vorapaxar to determine if and how THBD-PAR1 signaling promotes fibrosis progression in NASH. APPROACH AND RESULTS: We evaluated the THBD-PAR1 pathway in liver biopsies from patients with NAFLD. Chow-fed mice were treated with viral vectors to overexpress p16 in hepatocytes and induce replicative senescence. Effects on the THBD-PAR1 axis and regenerative capacity were assessed; the transcriptome of p16-overexpressing hepatocytes was characterized, and we examined how conditioned medium from senescent but viable (dubbed "undead") hepatocytes reprograms HSCs. Mouse models of NASH caused by genetic obesity or Western diet/CCl 4 were treated with vorapaxar to determine effects on hepatocyte senescence and liver damage. Inducing senescence upregulates the THBD-PAR1 signaling axis in hepatocytes and induces their expression of fibrogenic factors, including hedgehog ligands. Hepatocyte THBD-PAR1 signaling increases in NAFLD and supports sustained hepatocyte senescence that limits effective liver regeneration and promotes maladaptive repair. Inhibiting PAR1 signaling with vorapaxar interrupts this process, reduces the burden of 'undead' senescent cells, and safely improves NASH and fibrosis despite ongoing lipotoxic stress. CONCLUSION: The THBD-PAR1 signaling axis is a novel therapeutic target for NASH because blocking this pathway prevents accumulation of senescing but viable hepatocytes that generate factors that promote maladaptive liver repair.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Maeso-Díaz R, Du K, Pan C, et al. Targeting senescent hepatocytes using the thrombomodulin-PAR1 inhibitor vorapaxar ameliorates NAFLD progression. Hepatology. 2023. PMID: 37036206. doi:10.1097/HEP.0000000000000401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。